ArticleNature communications2018
Different patterns of clonal evolution among different sarcoma subtypes followed for up to 25 years.
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- Current Evidence for Circulating Tumor DNA in Sarcoma: Challenges and Opportunities for Clinical Application.Journal of surgical oncology · 2026Review
- Pharmacologic Resistance in Soft Tissue Sarcomas: Mechanisms, Biomarkers, and Translational Therapeutic Strategies.Cancers · 2026Review
- Intratumoral heterogeneity of cancer driver genomic alterations in myxoid liposarcomas.Cancer · 2025Article
- Evolutionary Pressures Shape Undifferentiated Pleomorphic Sarcoma Development and Radiotherapy Response.Cancer research · 2025Article
- Cellular origin and clonal evolution of human dedifferentiated liposarcoma.Nature communications · 2024Article
- MDM2 amplification in rod-shaped chromosomes provides clues to early stages of circularized gene amplification in liposarcoma.Communications biology · 2024Article
- Deciphering the role of FUS::DDIT3 expression and tumor microenvironment in myxoid liposarcoma development.Journal of translational medicine · 2024Article
- Case Series of Soft Tissue Sarcoma Patients with Brain Metastasis with Implications from Genomic and Transcriptomic Analysis.Cancer research and treatment · 2024Article
- Myxoid liposarcoma with nuclear pleomorphism: a clinicopathological and molecular study.Virchows Archiv : an international journal of pathology · 2024Article
- The diagnostic utility of DNA copy number analysis of core needle biopsies from soft tissue and bone tumors.Laboratory investigation; a journal of technical methods and pathology · 2022Article
- Targeted next-generation sequencing of circulating free DNA enables non-invasive tumor detection in myxoid liposarcomas.Molecular cancer · 2022Article
- Myxofibrosarcoma landscape: diagnostic pitfalls, clinical management and future perspectives.Therapeutic advances in medical oncology · 2022Review
- DIscBIO: A User-Friendly Pipeline for Biomarker Discovery in Single-Cell Transcriptomics.International journal of molecular sciences · 2021Article
- Genome wide methylation profiling of selected matched soft tissue sarcomas identifies methylation changes in metastatic and recurrent disease.Scientific reports · 2021Article
- The FUS-DDIT3 Interactome in Myxoid Liposarcoma.Neoplasia (New York, N.Y.) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
To compare clonal evolution in tumors arising through different mechanisms, we selected three types of sarcoma-amplicon-driven well-differentiated liposarcoma (WDLS), gene fusion-driven myxoid liposarcoma (MLS), and sarcomas with complex genomes (CXS)-and assessed the dynamics of chromosome and nucleotide level mutations by cytogenetics, SNP array analysis and whole-exome sequencing. Here we show that the extensive single-cell variation in WDLS has minor impact on clonal key amplicons in chromosome 12. In addition, only a few of the single nucleotide variants in WDLS were present in more than one lesion, suggesting that such mutations are of little significance in tumor development. MLS displays few mutations other than the FUS-DDIT3 fusion, and the primary tumor is genetically sometimes much more complex than its relapses, whereas CXS in general shows a gradual increase of both nucleotide- and chromosome-level mutations, similar to what has been described in carcinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.